CSL.AX - CSL Limited

ASX - ASX Delayed price. Currency in AUD

CSL Limited

45 Poplar Road
Parkville, VIC 3052
61 3 9389 1911

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Paul R. PerreaultMD, CEO & Exec. DirectorN/AN/A1957
Mr. David Mark Lamont ACA, BComChief Financial Officer1.85MN/A1966
Dr. Andrew Cuthbertson BMedSci, MBBS, Ph.D., FTSE, FAHMS, AOChief Scientific officer & Director of R&DN/AN/A1955
Mr. Gregory Boss J.D., BS(Hons)Exec. VP of Legal & Group Gen. CounselN/AN/A1961
Ms. Laurie Reed BS (Finance), MS (Organizational Development)Sr. VP of HRN/AN/A1964
Amounts are as of 31December,2017, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


CSL Limited engages in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, and internationally. It operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of bleeding disorders, including hemophilia and von Willebrand disease, primary and secondary immunodeficiency's, hereditary angioedema, neurological disorders, and inherited respiratory diseases. Its products are also used to prevent haemolytic diseases in newborns and infections in solid organ transplant recipients, as well as specific infections; and for urgent warfarin reversal in patients with acute major bleeding, as well as victims of trauma, shocks, and burns. In addition, this segment operates approximately 180 human blood plasma collection centers. Further, it conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and offers influenza vaccines. It also provides in-licensed vaccines and specialty pharmaceuticals; manufactures and markets diagnostics for immunohematology laboratories; and supplies a range of products, including antivenoms and Q fever vaccines. The company was founded in 1916 and is headquartered in Parkville, Australia.

Corporate governance

CSL Limited’s ISS governance QualityScore as of 1April,2018 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 5; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.